Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, GSK And Purdue Will Implement RFID Pilot Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will initiate a year-long, anti-counterfeiting pilot program for Viagra using radiofrequency identification technology in 2005

You may also be interested in...



FDA Developing "Stronger" Radio Frequency ID Guidance For Drug Tracking

FDA Acting Commissioner Crawford says there will be an update on the RFID guidance "about mid-year." The document will "urge in even stronger terms the wide use of this technology." Crawford believes the U.S. is behind EU countries in adopting RFID for tracking drugs.

FDA Developing "Stronger" Radio Frequency ID Guidance For Drug Tracking

FDA Acting Commissioner Crawford says there will be an update on the RFID guidance "about mid-year." The document will "urge in even stronger terms the wide use of this technology." Crawford believes the U.S. is behind EU countries in adopting RFID for tracking drugs.

FDA Anticounterfeiting Technology Guide Aims To Speed Industry Adoption

Agency will exercise enforcement discretion on labeling and GMP regulations that are triggered by radio frequency identification technology. FDA is working with EPC Global to establish standards of electronic pedigree.

Related Content

Topics

UsernamePublicRestriction

Register

PS058133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel